A novel tumor targeting drug carrier for optical imaging and therapy

Theranostics

Volumn 4, Issue 6, 2014, Pages 642-659

  Li, Rui ^a,d   Zheng, Ke ^c   Hu, Ping ^a   Chen, Zhuo ^a,d   Zhou, Shanyong ^a   Chen, Jincan ^a   Yuan, Cai ^a   Chen, Song ^a,d   Zheng, Wei ^b   Ma, En ^b   Zhang, Fengling ^c   Xue, Jinping ^c   Chen, Xueyuan ^b,d   Huang, Mingdong ^a,d  

^a FUJIAN INSTITUTE OF RESEARCH ON THE STRUCTURE OF MATTER   (China)

^b FUJIAN INSTITUTE OF RESEARCH ON THE STRUCTURE OF MATTER   (China)

^c FUZHOU UNIVERSITY   (China)

^d UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Amino terminal fragment of urokinase; Fluorescent molecular tomography; Human serum albumin; Phthalocyanine zinc; Tumor targeting; Urokinase receptor

Indexed keywords

CYTOTOXIC AGENT; DRUG CARRIER; PHTHALOCYANINE ZINC; RECOMBINANT HUMAN SERUM ALBUMIN; UROKINASE; UROKINASE RECEPTOR; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; ORGANOMETALLIC COMPOUND; PHOTOSENSITIZING AGENT; RECOMBINANT PROTEIN; SERUM ALBUMIN; ZN(II)-PHTHALOCYANINE;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; CANCER CELL LINE; CELL SURFACE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SPECIFICITY; DRUG STABILITY; DRUG TARGETING; FLUORESCENCE IMAGING; FLUORESCENT MOLECULAR TOMOGRAPHY; HUMAN; HUMAN CELL; HYDRODYNAMICS; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR CELL; ANIMAL; CHEMISTRY; DIAGNOSTIC USE; GENETICS; NEOPLASMS, EXPERIMENTAL; OPTICAL TOMOGRAPHY; PHOTOCHEMOTHERAPY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG CARRIERS; HUMANS; INDOLES; MALE; MICE; NEOPLASMS, EXPERIMENTAL; ORGANOMETALLIC COMPOUNDS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; RECOMBINANT PROTEINS; SERUM ALBUMIN; TOMOGRAPHY, OPTICAL; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84902511034     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.8527     Document Type: Article

References (71)

1. Peters T Jr. Serum albumin. Adv Protein Chem. 1985; 37: 161-245.
2. Peters T Jr. All about albumin: biochemistry, genetics, and medical applications. San Diego, USA: Academic Press, Inc. 1996.
3. Fanali G, di Masi A, Trezza V, et al. Human serum albumin: from bench to bedside. Mol Aspects Med. 2012; 33(3): 209-90.
4. Curry S. Lessons from the crystallographic analysis of small molecule binding to human serum albumin. Drug Metab Pharmacokinet. 2009; 24(4): 342-57.
5. Fasano M, Curry S, Terreno E, et al. The extraordinary ligand binding properties of human serum albumin. IUBMB Life. 2005; 57(12): 787-96.
6. Ashbrook JD, Spector AA, Santos EC, et al. Long chain fatty acid binding to human plasma albumin. J Biol Chem. 1975; 250(6): 2333-8.
7. Petitpas I, Petersen CE, Ha CE, et al. Structural basis of albumin-thyroxine interactions and familial dysalbuminemic hyperthyroxinemia. Proc Natl Acad Sci U S A. 2003; 100(11): 6440-5.
8. Zunszain PA, Ghuman J, Komatsu T, et al. Crystal structural analysis of human serum albumin complexed with hemin and fatty acid. BMC Struct Biol. 2003; 3: 6.
9. Zunszain PA, Ghuman J, McDonagh AF, et al. Crystallographic analysis of human serum albumin complexed with 4Z,15E-bilirubin-IX alpha. J Mol Biol. 2008; 381(2): 394-406.
10. Yamasaki K, Chuang VT, Maruyama T, et al. Albumin-drug interaction and its clinical implication. Biochim Biophys Acta. 2013; 1830(12): 5435-43.
11. Graeser R, Esser N, Unger H, et al. INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model. Invest New Drugs. 2010; 28(1): 14-9.
12. Morales J. Defining the role of insulin detemir in Basal insulin therapy. Drugs. 2007; 67(17): 2557-84.
13. Garg SK. The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes-a comprehensive review. Diabetes Technol Ther. 2010; 12(1): 11-24.
14. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005; 23(31): 7794-803.
15. Huai Q, Mazar AP, Kuo A, et al. Structure of human urokinase plasminogen activator in complex with its receptor. Science. 2006; 311(5761): 656-9.
16. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci. 2000; 57(1): 25-40.
17. Ploug M. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr Pharm Des. 2003; 9(19): 1499-528.
18. Lund IK, Illemann M, Thurison T, et al. uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy. Curr Drug Targets. 2011; 12(12): 1744-60.
19. Ploug M. Structure-driven design of radionuclide tracers for non-invasive imaging of uPAR and targeted radiotherapy. The tale of a synthetic peptide antagonist. Theranostics. 2013; 3(7): 467-76.
20. Persson M, Kjaer A. Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications. Clin Physiol Funct Imaging. 2013; 33(5): 329-37.
21. Knor S, Sato S, Huber T, et al. Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer. Eur J Nucl Med Mol Imaging. 2008; 35(1): 53-64.
22. Yang L, Mao H, Cao ZH, et al. Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles. Gastroenterology. 2009; 136(5): 1514-25.
23. Wang M, Lowik DW, Miller AD, et al. Targeting the urokinase plasminogen activator receptor with synthetic self-assembly nanoparticles. Bioconjug Chem. 2009; 20(1): 32-40.
24. Jing YQ, Tong CL, Zhang J, et al. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor. Cancer Res. 2009; 69(4): 1459-68.
25. Eefting D, Seghers L, Grimbergen JM, et al. A novel urokinase receptor-targeted inhibitor for plasmin and matrix metalloproteinases suppresses vein graft disease. Cardiovasc Res. 2010; 88(2): 367-75.
26. Hildenbrand R, Allgayer H, Marx A, et al. Modulators of the urokinase-type plasminogen activation system for cancer. Expert Opin Investig Drugs. 2010; 19(5): 641-52.
27. Kriegbaum MC, Persson M, Haldager L, et al. Rational targeting of the urokinase receptor (uPAR): development of antagonists and non-invasive imaging probes. Curr Drug Targets. 2011; 12(12): 1711-28.
28. Ngo JC, Jiang LG, Lin ZH, et al. Structural basis for therapeutic intervention of uPA/uPAR system. Curr Drug Targets. 2011; 12(12): 1729-43.
29. Abdalla MO, Karna P, Sajja HK, et al. Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy. J Control Release. 2011; 149(3): 314-22.
30. Jakobsche CE, McEnaney PJ, Zhang AX, et al. Reprogramming urokinase into an antibody-recruiting anticancer agent. ACS Chem Biol. 2012; 7(2): 316-21.
31. LeBeau AM, Duriseti S, Murphy ST, et al. Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer. Cancer Res. 2013; 73(7): 2070-81.
32. Chen JC, Chen NS, Huang JF, et al. Derivatizable phthalocyanine with single carboxyl group: synthesis and purification. Inorg Chem Commun. 2006; 9: 313-5.
33. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem. 2010; 21(5): 797-802.
34. Yuan C, Huai Q, Bian CB, et al. The expression, purification and crystallization of monomeric soluble human urokinase receptor. Prog Biochem Biophys. 2006; 33: 277-81.
35. Zhao GX, Yuan C, Bian CB, et al. Protein expression and preliminary crystallographic analysis of amino-terminal fragment of urokinase-type plasminogen activator. Protein Expr Purif. 2006; 49(1): 71-7.
36. Chen Z, Zhou SY, Chen JC, et al. Pentalysine beta-carbonylphthalocyanine zinc: an effective tumor-targeting photosensitizer for photodynamic therapy. ChemMedChem. 2010; 5(6): 890-8.
37. Seeliger D, de Groot BL. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J Comput Aided Mol Des. 2010; 24(5): 417-22.
38. Brunger AT. Version 1.2 of the Crystallography and NMR system. Nat Protoc. 2007; 2(11): 2728-33.
39. Stephens RW, Pedersen AN, Nielsen HJ, et al. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem. 1997; 43(10): 1868-76.
40. Kobayashi K, Kuwae S, Ohya T, et al. High-level expression of recombinant human serum albumin from the methylotrophic yeast Pichia pastoris with minimal protease production and activation. J Biosci Bioeng. 2000; 89(1): 55-61.
41. Moreira LM, dos Santos FV, Lyon JP, et al. Photodynamic therapy: porphyrins and phthalocyanines as photosensitizers. Aust J Chem. 2008; 61: 741-54.
42. Wainwright M. Photodynamic therapy: the development of new photosensitisers. Anticancer Agents Med Chem. 2008; 8: 280-91.
43. Garg AD, Nowis D, Golab J, et al. Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity. Apoptosis. 2010; 15(9): 1050-71.
44. Huang Z. A review of progress in clinical photodynamic therapy. Technol Cancer Res Treat. 2005; 4(3): 283-93.
45. Huang Z, Xu HP, Meyers AD, et al. Photodynamic therapy for treatment of solid tumors - potential and technical challenges. Technol Cancer Res Treat. 2008; 7(4): 309-20.
46. Jeong H, Huh M, Lee SJ, et al. Photosensitizer-conjugated human serum albumin nanoparticles for effective photodynamic therapy. Theranostics. 2011; 1: 230-9.
47. Lebedeva NS. Aggregation properties of water-soluble metal phthalocyanines: effect of ionic strength of solution. Russ Chem Bull. 2004; 53: 2674-83.
48. Yang F, Bian CB, Zhu LL, et al. Effect of human serum albumin on drug metabolism: structural evidence of esterase activity of human serum albumin. J Struct Biol. 2007; 157(2): 348-55.
49. Zhu LL, Yang F, Chen LQ, et al. A new drug binding subsite on human serum albumin and drug-drug interaction studied by X-ray crystallography. J Struct Biol. 2008; 162(1): 40-9.
50. Guo SH, Shi XL, Yang F, et al. Structural basis of transport of lysophospholipids by human serum albumin. Biochem J. 2009; 423(1): 23-30.
51. Vivian JT, Callis PR. Mechanisms of tryptophan fluorescence shifts in proteins. Biophys J. 2001; 80(5): 2093-109.
52. Abi-Habib RJ, Singh R, Liu SH, et al. A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types. Mol Cancer Ther. 2006; 5(10): 2556-62.
53. Li LS, Luo ZP, Chen Z, et al. Enhanced photodynamic efficacy of zinc phthalocyanine by conjugating to heptalysine. Bioconjug Chem. 2012; 23(11): 2168-72.
54. Xu P, Chen JC, Chen Z, et al. Receptor-targeting phthalocyanine photosensitizer for improving antitumor photocytotoxicity. PLoS One. 2012; 7(5): e37051.
55. Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer. 2006; 6: 535-45.
56. Mroz P, Hashmi JT, Huang YY, et al. Stimulation of anti-tumor immunity by photodynamic therapy. Expert Rev Clin Immunol. 2011; 7(1): 75-91.
57. Babson AL, Winnick T. Protein transfer in tumor-bearing rats. Cancer Res. 1954; 14: 606-11.
58. Wilkinso.P, Jeremy R, Brooks FP, et al. Mechanism of hypoalbuminemia in rheumatoid arthritis. Ann Intern Med. 1965; 63: 109-14.
59. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer-chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986; 46: 6387-92.
60. Isele U, Schieweck K, Kessler R, et al. Pharmacokinetics and body distribution of liposomal zinc phthalocyanine in tumor-bearing mice: influence of aggregation state, particle size, and composition. J Pharm Sci. 1995; 84(2): 166-73.
61. Zhang ZB, Jin HT, Bao J, et al. Intravenous repeated-dose toxicity study of ZnPcS2P2-based-photodynamic therapy in Wistar rats. Photochem Photobiol Sci. 2006; 5(11): 1006-17.
62. Liu W, Chen NS, Jin HT, et al. Intravenous repeated-dose toxicity study of ZnPcS2P2-based-photodyamic therapy in beagle dogs. Regul Toxicol Pharmacol. 2007; 47(3): 221-31.
63. Smirnova ZS, Oborotova NA, Makarova OA, et al. Efficiency and pharmacokinetics of photosense: a new liposomal photosensitizer formulation based on aluminum sulfophthalocyanine. Khim Farm Zh. 2005; 39: 3-7.
64. Lin L, Gardsvoll H, Huai Q, et al. Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy. J Biol Chem. 2010; 285(14): 10982-92.
65. Heneweer C, Holland JP, Divilov V, et al. Magnitude of enhanced permeability and retention effect in tumors with different phenotypes: 89Zr-albumin as a model system. J Nucl Med. 2011; 52(4): 625-33.
66. Elsadek B, Kratz F. Impact of albumin on drug delivery - new applications on the horizon. J Control Release. 2012; 157(1): 4-28.
67. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008; 132(3): 171-83.
68. Frenkel YV, Clark AD Jr, Das K, et al. Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability. J Med Chem. 2005; 48(6): 1974-83.
69. Shoichet BK. Interpreting steep dose-response curves in early inhibitor discovery. J Med Chem. 2006; 49(25): 7274-7.
70. Brasseur N, Langlois R, La Madeleine C, et al. Receptor-mediated targeting of phthalocyanines to macrophages via covalent coupling to native or maleylated bovine serum albumin. Photochem Photobiol. 1999; 69(3): 345-52.
71. Anatelli F, Mroz P, Liu Q, et al. Macrophage-targeted photosensitizer conjugate delivered by intratumoral injection. Mol Pharm. 2006; 3(6): 654-64.